



ASX ANNOUNCEMENT

26 October 2018

CardieX Wins Contract to Supply Medical Devices for International Pharmaceutical Trial

Highlights:

- CardieX subsidiary to supply SphygmoCor® systems in new clinical trial.
- Study will be multinational assessing heart failure treatment.
- Major international pharmaceutical group managing trial.
- Trial to run for 18 months across US and Europe.
- Cost of heart failure to US circa US\$30 billion annually.
- Trial seen as first phase of larger commercial opportunity for CardieX group.

CardieX Limited (ASX: CDX), announced today that its AtCor Medical subsidiary has executed a new contract to supply SphygmoCor® systems and clinical trial support services in a multinational clinical study that will assess the central hemodynamic effects of a novel compound for the treatment of heart failure.

This trial, which is being conducted by a major international pharmaceutical company and existing AtCor Medical client, will be conducted in multiple European countries as well as the United States and run for 18 months. The contract value is approximately A\$0.3 million.

This is a Phase II trial, so it is anticipated to open a larger financial opportunity for AtCor Medical when the clinical program progresses to Phase III of development.

AtCor's SphygmoCor® technology has been utilized by researchers and clinicians for the non-invasive assessment of central blood pressure for approximately two decades. It is currently being used in all 20 hospitals on the U.S. News Best Hospitals 2017-2018 Honor Roll and has been leveraged by pharmaceutical companies worldwide to investigate the effects of novel drugs on heart-vascular interactions.

The information provided through SphygmoCor® assessments is especially beneficial in heart failure drug development where the challenges of bringing a novel therapy to the market are well documented. SphygmoCor XCEL's robust data output and ease-of-use make it a well-suited, easily integrated tool for clinical trials of all sizes.

Craig Cooper, CEO of CardieX, said: "Coupled with the recent expansion of a number of existing clinical trial agreements, our AtCor group is continuing its strong momentum in the clinical trial support sector. The therapeutic focus for this new clinical trial is heart failure - which is estimated to



affect over 5.5 million people annually and cost the US health care system over US\$30 billion per year. We are very pleased to have our technology utilized in multiple ongoing heart failure trials in partnership with some of the leading global pharmaceutical companies as we jointly strive to find novel solutions to this costly disease.”

For more information please contact:

Chief Executive Officer

Craig Cooper

Ph: +61 429 993 399

ccooper@cardiex.com

Investor Relations

Peter Taylor

Ph: +61 412 036 231

peter@nwrcommunications.com.au

About CardieX

CardieX is a Sydney based global health technology company focused on developing technology solutions for large-scale population health disorders.